This company has been marked as potentially delisted and may not be actively trading. NASDAQ:OPT Opthea (OPT) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsFDA EventsTrendsBuy This Stock About Opthea Stock (NASDAQ:OPT) Get Opthea alerts:Sign Up Key Stats Today's Range$3.41▼$3.4150-Day Range$3.41▼$3.4152-Week Range$1.79▼$6.30VolumeN/AAverage VolumeN/AMarket Capitalization$524.84 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Opthea Limited (NASDAQ:OPT) is a clinical-stage biopharmaceutical company focused on developing novel therapies for retinal vascular diseases. The company’s lead product candidate, OPT-302, is designed to inhibit vascular endothelial growth factors C and D (VEGF-C/D) and is being evaluated as a potential treatment for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Opthea’s research strategy aims to complement existing anti-VEGF-A therapies by providing a broader blockade of the VEGF family to address residual vision loss in patients receiving standard care. OPT-302 has advanced through multiple clinical trials, including a Phase 2b study in wet AMD patients and a Phase 1/2 trial in DME patients. Data from these trials have demonstrated promising safety and efficacy signals, including improvements in visual acuity and reductions in retinal fluid. Opthea collaborates with global contract research organizations and ophthalmology centers to support its clinical development program, with ongoing studies designed to establish optimal dosing regimens and confirm long-term benefits. Founded in 2009 based on research conducted at the Walter and Eliza Hall Institute in Melbourne, Opthea is headquartered in Melbourne, Australia, with strategic operations in North America. The company’s management team combines expertise in ophthalmology, clinical development, regulatory affairs and commercialization to advance its pipeline toward potential regulatory approvals. Opthea is committed to addressing unmet medical needs in retinal diseases and to creating value for patients, healthcare providers and investors through its innovative therapeutic approach.AI Generated. May Contain Errors. Read More Opthea Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks1st Percentile Overall ScoreOPT MarketRank™: Opthea scored higher than 1% of companies evaluated by MarketBeat, and ranked 859th out of 863 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.5 / 5Analyst RatingSell Consensus RatingOpthea has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageOpthea has received no research coverage in the past 90 days.Read more about Opthea's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Opthea are expected to grow in the coming year, from ($1.39) to ($0.67) per share. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for OPT. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldOpthea does not currently pay a dividend.Dividend GrowthOpthea does not have a long track record of dividend growth. News and Social Media0.0 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Opthea this week, compared to 0 articles on an average week. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Opthea insiders have not sold or bought any company stock.Percentage Held by Insiders3.20% of the stock of Opthea is held by insiders.Percentage Held by Institutions55.95% of the stock of Opthea is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Opthea's insider trading history. Receive OPT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Opthea and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. OPT Stock News HeadlinesHotCopper highlights wk 23: DXN jumps +600%; NST read the riot act, Opthea, 14D & moreJune 6, 2026 | msn.comWednesday's HotCopper trends: Opthea, Northern Star, Dreadnought, and other daily topicsJune 3, 2026 | msn.comRead this warning immediatelyPorter Stansberry, founder of one of the world's largest financial research firms, says he's breaking the biggest story of his 26-year career. A famous historian whose books have sold over 45 million copies in 65 languages is warning of a structural shift so large it has only one historical parallel - 1776. One Stanford economist calls it 'the biggest change ever - bigger than electricity, bigger than the steam engine.' Stansberry outlines the stocks to buy, the stocks to sell, and three money moves to position yourself on the right side of this shift.June 10 at 1:00 AM | Porter & Company (Ad)Why is this ASX share crashing 97% today?June 2, 2026 | msn.comOpthea to host corporate update webinarDecember 11, 2025 | msn.comOpthea Limited Provides Corporate Update in Investor PresentationAugust 20, 2025 | msn.comOpthea Provides Corporate UpdateAugust 18, 2025 | globenewswire.comBiocurious: Dimerix could be riding big and beautiful kidney drug success earlier than expectedJuly 2, 2025 | msn.comSee More Headlines OPT Stock Analysis - Frequently Asked Questions When did Opthea IPO? Opthea (OPT) raised $161 million in an initial public offering on Friday, October 16th 2020. The company issued 9,300,000 shares at $17.26 per share. Citigroup and SVB Leerink acted as the underwriters for the IPO and Oppenheimer & Co. and Truist Securities were co-managers. What other stocks do shareholders of Opthea own? Based on aggregate information from My MarketBeat watchlists, some other companies that Opthea investors own include PayPal (PYPL), Sunrun (RUN), Avino Silver & Gold Mines (ASM), Qualcomm (QCOM), Ross Stores (ROST), Adobe (ADBE). Company Calendar Today6/10/2026Investor update6/11/2026Fiscal Year End6/30/2026AGM 20267/02/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:OPT CIK1815620 Webwww.opthea.com Phone61-3-9826-0399FaxN/AEmployees8Year Founded2012Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio0.22 Quick Ratio0.22 Sales & Book Value Annual Sales$25 thousand Price / Sales20,993.46 Cash FlowN/A Price / Cash FlowN/A Book Value($1.31) per share Price / Book-2.60Miscellaneous Outstanding Shares153,911,000Free Float165,525,000Market Cap$524.84 million OptionableNot Optionable Beta1.12 Social Links 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce. Get This Free Report This page (NASDAQ:OPT) was last updated on 6/10/2026 by MarketBeat.com Staff. From Our PartnersHow to claim a stake in SpaceX before the June 12 IPOSpaceX is expected to go public on June 12 - and for the first time, everyday investors may have a way in befo...Brownstone Research | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredOpenAI is preparing to go publicOpenAI - the company behind ChatGPT - has begun filing confidential paperwork for what could be the largest IP...InvestorPlace | SponsoredThis is the worst news for stocks in 50 yearsGoldman Sachs and Morgan Stanley are issuing a rare warning: what's ahead for U.S. stocks could be the worst e...TradeSmith | SponsoredThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Be...Banyan Hill Publishing | SponsoredHe Called NVIDIA at $1.10 – Now He Says, “SELL”The analyst who called NVIDIA at $1.10 now says sell. According to Alexander Green, Chief Investment Strategis...The Oxford Club | SponsoredOne hidden supplier shipped 5 billion parts to SpaceXMost investors are focused on the historic $1.75 trillion SpaceX IPO expected around June 30. But there's a le...Weiss Ratings | SponsoredIn 30 days, you'll wish you'd read this emailA small power equipment company with $1.5 billion in orders is flying under the radar - but not for long. When...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Opthea Limited Unsponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Opthea With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
